A prospective study of efficacy and safety of atezolizumab for patients with non-small cell lung cancer and interstitial pneumonia
Phase 1
Recruiting
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000034849
- Lead Sponsor
- ational Health Organization Kyoto Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Severe renal dysfunction (eGFR < 30 ml/min/1.73m2) Severe liver dysfunction (AST > 100 IU/ml, ALT > 100 IU/ml, or T-Bil > 3 mg/dl) Respiratory failure (PaO2 < 60 mmHg or PaCO2 >45 mmHg on under room air atmosphere) Prior history of acute exacerbation of interstitial pneumonia or drug-induced pneumonitis Impossibility to obtain a written consent form Impossibility to obtain sufficient data of outcomes Judgement of unsuitability as a subject from researchers
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method